Scleroderma: Health services utilization from patients' perspective

Journal of Rheumatology

Volumn 33, Issue 6, 2006, Pages 1123-1127

  Johnson, Sindhu R ^a   Carette, Simon ^a   Dunne, James V ^b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

Access to care; Health services utilization; Patient survey; Scleroderma; Systemic sclerosis

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; ELECTROCARDIOGRAPHY; EVALUATION; FEMALE; FOLLOW UP; GASTROSCOPY; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEDICAL SPECIALIST; PRIORITY JOURNAL; QUESTIONNAIRE; SCLERODERMA; SCREENING TEST; SKINFOLD THICKNESS; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

ADULT; AGED; ATTITUDE TO HEALTH; CANADA; FEMALE; HEALTH SERVICES; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; SCLERODERMA, SYSTEMIC;

EID: 33744762166     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-54.
2. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001;44:1359-62.
3. Young MA, Rose S, Reynolds JC. Gastrointestinal manifestations of scleroderma. Rheum Dis Clin North Am 1996;22:797-823.
4. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine Baltimore 2002;81:154-67.
5. Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine Baltimore 1983;62:335-52.
6. Livi R, Teghini L, Pignone A, Generini S, Matucci-Cerinic M, Cagnoni M. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis 2002;61:682-6.
7. Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zuckner J. Heart disease in systemic sclerosis. Semin Arthritis Rheum 1989;19:191-200.
8. Hong P, Pope JE, Ouimet JM, Rullan E, Seibold JR. Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis. J Rheumatol 2004;31:508-13.
9. Johnson SR, Dewar C. Erectile dysfunction and scleroderma. J Rheumatol 2004;31:2091-2.
10. Denton CP, Black CM. Scleroderma-clinical and pathological advances. Best Pract Res Clin Rheumatol 2004;18:271-90.
11. Denton CP. Overview of the treatment and prognosis of scleroderma adults. In: Rose BD, editor. UpToDate. Wellesley, MA: UpToDate, 2005.
12. Silver RM, Clements PJ. Interstitial lung disease in systemic sclerosis: Optimizing evaluation and management. Scleroderma Care Res 2003;1:3-11.
13. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
14. Askew LJ, Beckett VL, An KN, Chao EY. Objective evaluation of hand function in scleroderma patients to assess effectiveness of physical therapy. Br J Rheumatol 1983;22:224-32.
15. Krizek C, Roberts C, Ragan R, Ferrara JJ, Lord B. Gender and cancer support group participation. Cancer Pract 1999;7:86-92.
16. Lasker JN, Sogolow ED, Sharim RR. The role of an online community for people with a rare disease: content analysis of messages posted on a primary biliary cirrhosis mailing list. J Med Internet Res 2005;7:e10.
17. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40:734-42.
18. Englert H, Small-McMahon J, Chambers P, et al. Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999;29:36-41.
19. Zhou X, Tan FK, Wang N, et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003;48:2585-92.
20. Assassi S, Mayes MD. The genetics of scleroderma. What every rheumatologist should know. Scleroderma Care Res 2003;1:3-11.
21. Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319-24.
22. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
23. Fahlman N. Scleroderma: Managing scleroderma. Scleroderma Society of Canada; 2004.
24. Edworthy S. Scleroderma: Medical tests. Scleroderma Society of Canada; 2004.
25. Claudepierre P, Flipo RM, Sibilia J, et al. Patient knowledge of their disease: a French multicenter study in ankylosing spondylitis. Joint Bone Spine 2004;71:550-6.
26. Goldenberg DL, Mason JH, De Horatius R, et al. Rheumatology education in United States medical school. Arthritis Rheum 1981;24:1561-6.
27. Renner BR, DeVellis BM, Ennett ST, et al. Clinical rheumatology training of primary care physicians: the resident perspective. J Rheumatol 1990;17:666-72.
28. Bolumar F, Ruiz MT, Hernandez I, Pascual E. Reliability of the diagnosis of rheumatic conditions at the primary health care level. J Rheumatol 1994;21:2344-8.
29. Stross JK, Bole GG. The impact of a new rheumatologist on the management of rheumatic disease patients in community hospitals. Arthritis Rheum 1983;26:1033-6.
30. Kidd BL, Cawley MI. Delay in diagnosis of spondarthritis. Br J Rheumatol 1988;27:230-2.
31. Shipton D, Glazier RH, Guan J, Badley EM. Effects of use of specialty services on disease-modifying antirheumatic drug use in the treatment of rheumatoid arthritis in an insured elderly population. Med Care 2004;42:907-13.
32. Williams JI, Badley EM. The role of primary care physicians in treating arthritis. In: Williams JI, Badley EM, editors. Patterns of health care in Ontario. Arthritis and realted conditions. An ICES practice atlas. Toronto: Institute for Clinical Evaluative Sciences, 1998:63-92.
33. Steen VD, Medsger TA, Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.
34. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
35. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
36. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
37. Clements P, Furst D, Silver R, et al. The scleroderma lung study shows the beneficial effects of cyclophosphamide over placebo in systemic sclerosis [abstract]. Arthritis Rheum 2005;52 Suppl:S257.
38. Khanna D, Clements PJ, Furst D, Park G, Merkel PA. Diagnostic and management preferences for lung disease in scleroderma: results of survey of rheumatologists. Scleroderma Care Res 2004;2:3-11.
39. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.